US Stock Insider Trading | Lescon Pharmaceuticals disclosed two insider trading transactions on February 23

K-LinePoet · 2026-02-25T00:40:20+00:00

February 23, 2026, Lixun Pharmaceutical (LXRX) disclosed two insider trading transactions. Director DEBBANE RAYMOND purchased 100,000 shares on February 20, 2026.【Recent Insider Trading】| Disclosure Date | Position | Name | Transaction Date | Buy/Sell | Quantity | Price per Share (USD) | Total Amount (USD) || --- | --- | --- | --- | --- | --- | --- | --- || February 23, 2026 | Director | DEBBANE RAYMOND | February 19, 2026 | Buy | 50,000 | 1.44 | 72,000 || February 23, 2026 |

K-LinePoet

2026-02-25 00:40:20

On February 23, 2026, Lexicon Pharmaceuticals (LXRX) disclosed two insider trading transactions. Director DEBBANE RAYMOND purchased 100,000 shares on February 20, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 23, 2026	Director	DEBBANE RAYMOND	February 19, 2026	Buy	50,000	1.44	$72,000
February 23, 2026	Director	DEBBANE RAYMOND	February 20, 2026	Buy	100,000	1.48	$147,800
February 18, 2026	Director	DEBBANE RAYMOND	February 17, 2026	Buy	76,900	1.31	$100,500
February 18, 2026	Director	DEBBANE RAYMOND	February 18, 2026	Buy	133,700	1.32	$176,500
February 18, 2026	Director	DEBBANE RAYMOND	February 13, 2026	Buy	58,000	1.31	$75,900
March 3, 2025	Executive	Alexander Kristen	February 28, 2025	Sell	17,900	0.67	$12,000
March 3, 2025	Executive	McDermott Wendy	February 28, 2025	Sell	30,000	0.67	$20,100
March 3, 2025	Executive	Granowitz Craig B	February 28, 2025	Sell	65,300	0.67	$43,800
March 3, 2025	Executive	MAIN ALAN J	February 28, 2025	Sell	43,400	0.67	$29,100
March 3, 2025	Executive	Crum Brian T	February 28, 2025	Sell	45,600	0.67	$30,600

【Company Profile】

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on researching and achieving breakthroughs in human disease treatment. Using gene knockout technology and an advanced integrated medical platform, the company has systematically studied the physiological and behavioral functions of nearly 5,000 genes in mice, evaluated the potential of proteins encoded by corresponding human genes as drug targets, and identified and validated over 100 targets suitable for drug discovery in vivo (or in living organisms). For targets deemed highly valuable for medicinal purposes, the company is committed to developing potential new drugs. It was incorporated in Delaware, USA, on July 7, 1995, and began operations in September 1995.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.